Skip to main navigation Skip to search Skip to main content

Staging fluorodeoxyglucose positron emission tomography/computed tomography for muscle-invasive bladder cancer: a nationwide population-based study

  • Anke Richters
  • , Noor van Ginkel
  • , Richard P. Meijer
  • , Maurits Wondergem
  • , Ivo Schoots
  • , André N. Vis
  • , Lambertus A.L.M. Kiemeney
  • , Bas W.G. van Rhijn
  • , J. Alfred Witjes
  • , Katja K.H. Aben
  • , Laura S. Mertens*
  • *Corresponding author for this work
  • Netherlands Comprehensive Cancer Organization (IKNL)
  • Radboud University Medical Center
  • Netherlands Cancer Institute
  • Amsterdam UMC
  • Utrecht University
  • University of Regensburg

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Scopus)
46 Downloads (Pure)

Abstract

Objective: To provide insight into the use and staging information on lymph-node involvement added by fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in patients with muscle-invasive bladder cancer (MIBC), based on a nationwide population-based cohort study. Patients and methods: We analysed a nationwide cohort of patients with MIBC without signs of distant metastases, newly diagnosed in the Netherlands between November 2017 and October 2019. From this cohort, we selected patients who underwent pre-treatment staging with CT only or CT and FDG-PET/CT. The distribution of patients, disease characteristics, imaging findings, nodal status (clinical nodal stage cN0 vs cN+) and treatment were described for each imaging modality group (CT only vs CT and FDG-PET/CT). Results: We identified 2731 patients with MIBC: 1888 (69.1%) underwent CT only; 606 (22.2%) underwent CT and FDG-PET/CT, 237 (8.6%) underwent no CT. Of the patients who underwent CT only, 200/1888 (10.6%) were staged as cN+, vs 217/606 (35.8%) who underwent CT and FDG-PET/CT. Stratified analysis showed that this difference was found in patients with clinical tumour stage (cT)2 as well as cT3/4 MIBC. Of patients who underwent both imaging modalities and were staged with CT as cN0, 109/498 (21.9%) were upstaged to cN+ based on FDG-PET/CT. Radical cystectomy (RC) was the most common treatment within both imaging groups. Preoperative chemotherapy was more frequently applied in cN+ disease and in FDG-PET/CT-staged patients. Concordance of pathological N stage after upfront RC was higher among patients staged as cN+ with CT and FDG-PET/CT (50.0% pN+) than those staged as cN+ with only CT (39.3%). Conclusion: Patients with MIBC who underwent pre-treatment staging with FDG-PET/CT were more often staged as lymph node positive, regardless of cT stage. In patients with MIBC who underwent CT and FDG-PET/CT, FDG-PET/CT led to clinical nodal upstaging in approximately one-fifth. Additional imaging findings may influence subsequent treatment strategies.

Original languageEnglish
Pages (from-to)420-427
Number of pages8
JournalBJU International
Volume132
Issue number4
Early online date28 May 2023
DOIs
Publication statusPublished - Oct 2023

Bibliographical note

Funding Information:
The BlaZIB study is supported by the Dutch Cancer Society (KWF; IKNL 2015‐7914). The funding agency had no further role in this study.

Publisher Copyright:
© 2023 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Staging fluorodeoxyglucose positron emission tomography/computed tomography for muscle-invasive bladder cancer: a nationwide population-based study'. Together they form a unique fingerprint.

Cite this